Degenerative disease

Cognition Therapeutics Reviews 2020 Accomplishments and Provides 2021 Guidance

Retrieved on: 
Tuesday, January 5, 2021
Branches of biology, Cognitive disorders, Biology, Abnormal psychology, Alzheimer's disease, Dementia, Psychiatric diagnosis, Degenerative disease, Clinical medicine

In addition, Ms. Ricciardi will be participating in numerous one-on-one meetings during the week of the annual JP Morgan Healthcare Conference, January 11-14, 2021.

Key Points: 
  • In addition, Ms. Ricciardi will be participating in numerous one-on-one meetings during the week of the annual JP Morgan Healthcare Conference, January 11-14, 2021.
  • During her presentation, Ms. Ricciardi discusses Cognitions clinical status in Alzheimers disease and other neurodegenerative disorders as well as anticipated milestones for 2021.
  • In 2021, the company is hosting for the fifth time, the International Symposium on sigma-2 Receptors: Role in Health and Disease.
  • Cognition Therapeutics, Inc. has discovered and is developing a pipeline of novel, disease-modifying, oral drug candidates to treat a broad array of neurodegenerative and neuro-ophthalmic disorders.

Octave Bioscience Secures $32 Million Series B Financing

Retrieved on: 
Thursday, December 17, 2020
Data management, Health, Medical devices, Technology, Other Technology, General Health, Biotechnology, Senescence, Branches of biology, Programming languages, Software, GNU Octave, Degenerative disease, Neurodegeneration, Multiple Sclerosis, the Octave Bioscience Comprehensive Care Platform, Octave Bioscience, Northpond Ventures

Octave Bioscience , the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, today announced the completion of a $32 million Series B financing.

Key Points: 
  • Octave Bioscience , the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, today announced the completion of a $32 million Series B financing.
  • Neurodegenerative diseases represent a new and important frontier for innovation in the quest to address significant unmet needs and transform care, said William A. Hagstrom, Founder and CEO of Octave Bioscience.
  • Octave Bioscience is completing development of a comprehensive, first-in-class care management platform for neurodegenerative disease, beginning with MS.
  • Octave Bioscience was founded to deliver an end-to-end care management platform for multiple sclerosis as well as a full range of neurodegenerative diseases.

Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN Mutations

Retrieved on: 
Friday, December 11, 2020
Cognitive disorders, Psychiatric diagnosis, Branches of biology, Dementia, Psychiatry, Neuroscience, Learning disabilities, Temporal lobe, Frontotemporal dementia, Granulin, Alzheimer's disease, Degenerative disease

Dosing the first patient in our PROCLAIM clinical trial marks an important milestone in our efforts to advance a potentially disease-modifying treatment for patients with frontotemporal dementia with GRN mutations, said Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail.

Key Points: 
  • Dosing the first patient in our PROCLAIM clinical trial marks an important milestone in our efforts to advance a potentially disease-modifying treatment for patients with frontotemporal dementia with GRN mutations, said Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail.
  • We are excited to progress clinical development of PR006 and to bring forward a much-needed therapy for this rapidly progressing neurodegenerative disease.
  • The PROCLAIM trial is a Phase 1/2 open-label trial investigating the safety and tolerability of PR006 as well as key biomarkers and exploratory efficacy endpoints.
  • Frontotemporal dementia (FTD) is the second most common cause of dementia in people under the age of 65, after Alzheimers disease.

New memoir narrates one woman’s story of living with a rare disability and how she did not let the disease beat her

Retrieved on: 
Tuesday, November 10, 2020
Neurological disorders, Medicine, Branches of biology, Rare diseases, Ataxia, Stroke, Disease, Friedreich's ataxia, Degenerative disease

After struggling for years to find the right support, Seamand is unwavering in her journey to get better and prove others wrong.

Key Points: 
  • After struggling for years to find the right support, Seamand is unwavering in her journey to get better and prove others wrong.
  • Friedreichs Ataxia is a rare disability with very little public awareness, the author states.
  • Let Me Be Your Voice aims to encourage those suffering from FA and other degenerative diseases to never give up hope.
  • By sharing her story, she wishes to educate others about the disease and improve understanding of the condition.

Global Neurodegenerative Disorder Therapeutics Market Report 2020: Impact of Patent Expiry and Entry of Biosimilars & Impact of COVID-19

Retrieved on: 
Monday, November 2, 2020
Branches of biology, Senescence, Neurological disorders, Biology, Neuroscience, Neurodegeneration, Degenerative disease, Estrogen and neurodegenerative diseases

The global market for neurodegenerative disorder therapeutics is predicted to grow at a CAGR of 7.21% over the forecast period of 2020-2030.

Key Points: 
  • The global market for neurodegenerative disorder therapeutics is predicted to grow at a CAGR of 7.21% over the forecast period of 2020-2030.
  • The market is favored by the development of neurodegenerative disorder therapeutics for several clinical areas such as Multiple sclerosis, Parkinson's disease, Alzheimer's disease, Spinal Muscular Atrophy, Huntington disease, and other neurodegenerative disorders.
  • The increase in the geriatric population and incurable neurodegenerative disorders across the globe are expected to translate into significantly higher demand for neurodegenerative disorder therapeutics market.
  • The clinical trial landscape of different neurodegenerative disorders has been on the rise in recent years, and this will fuel the neurodegenerative disorder therapeutics market in the future.

Axovant Gene Therapies to Present AXO-Lenti-PD Program Update During Virtual Parkinson’s Disease R&D Day on October 30, 2020

Retrieved on: 
Thursday, October 29, 2020
Branches of biology, Lipid storage disorders, Rare diseases, Health, Clinical medicine, GM2 gangliosidoses, Sandhoff disease, Gangliosidosis, Tay–Sachs disease, GM1, Axovant Sciences, Degenerative disease

The Company expects to provide an update on program timelines in the first quarter of 2021 or as program timelines are clarified.

Key Points: 
  • The Company expects to provide an update on program timelines in the first quarter of 2021 or as program timelines are clarified.
  • Axovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases.
  • Our current pipeline of gene therapy candidates target GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinsons disease.
  • Axovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Inflammasome Therapeutics Receives Grant to Develop Sustained-Release Bioerodible Birth Control Implant

Retrieved on: 
Wednesday, September 16, 2020
Biotechnology, Diabetes, Health, Branches of biology, Cytokines, Inflammasome, Degenerative disease, Contraceptive implant, Biology, Interleukin 1 beta

Inflammasome Therapeutics, a private, science-based company developing therapies for prevalent, degenerative diseases as well as sustained-release drug delivery systems, announced it has been awarded a $1.0-million grant to develop a long-term bioerodible birth control implant.

Key Points: 
  • Inflammasome Therapeutics, a private, science-based company developing therapies for prevalent, degenerative diseases as well as sustained-release drug delivery systems, announced it has been awarded a $1.0-million grant to develop a long-term bioerodible birth control implant.
  • After the drug has been fully released the implant will dissolve in the body requiring no removal as is current practice with the existing levonorgestrel implant in use today.
  • Dr. Paul Ashton, CEO of Inflammasome Therapeutics said, We are delighted to work with the foundation on this important program.
  • Inflammasome Therapeutics ( www.inflam.com ) is a science-based company founded to develop therapies for prevalent, degenerative diseases such as Alzheimers disease, multiple sclerosis, macular degeneration and type 2 diabetes.

Alector Doses First Patient in Pivotal Phase 3 INFRONT-3 Trial Evaluating AL001 in Patients with Frontotemporal Dementia

Retrieved on: 
Friday, July 24, 2020
Branches of biology, Brain, Cognitive disorders, Psychiatric diagnosis, Clinical medicine, Frontal lobe, Frontotemporal dementia, Temporal lobe, Granulin, Dementia, Degenerative disease, Biomarker

There are multiple heritable forms of FTD, and FTD-GRN patients represent 5% to 10% of all people with FTD.

Key Points: 
  • There are multiple heritable forms of FTD, and FTD-GRN patients represent 5% to 10% of all people with FTD.
  • The initiation of our global pivotal Phase 3 trial of AL001 is a significant step towards achieving our mission of helping patients suffering from FTD and other neurodegenerative diseases, said Robert Paul, M.D., Ph.D., chief medical officer of Alector.
  • Our Phase 3 study has been designed to measure slowing of disease progression in both symptomatic and pre-symptomatic FTD-GRN patients.
  • The Companys product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimers disease.

SparingVision Receives European Orphan Designation for its Drug Candidate SPVN06 Dedicated to Inherited Retinal Dystrophies

Retrieved on: 
Tuesday, June 30, 2020
Biotechnology, Other Health, Health, Pharmaceutical, Optical, Ophthalmology, Branches of biology, Medical specialties, Blindness, Channelopathies, RTT, Retinitis pigmentosa, Retinal degeneration, Retinitis, Degenerative disease, Foundation Fighting Blindness, PRPF31

SparingVision, a biotechnology company specializing in the research and development of innovative therapies for treatment of hereditary retinal degenerative diseases such as retinitis pigmentosa, announces today the decision of the European Commission to grant Orphan Drug Designation for SPVN06 for the treatment of inherited retinal dystrophies.

Key Points: 
  • SparingVision, a biotechnology company specializing in the research and development of innovative therapies for treatment of hereditary retinal degenerative diseases such as retinitis pigmentosa, announces today the decision of the European Commission to grant Orphan Drug Designation for SPVN06 for the treatment of inherited retinal dystrophies.
  • The decision is based on a positive opinion from the European Medicine Agencys (EMA) Committee for Orphan Medicinal Products (COMP).
  • SPVN06 is a breakthrough treatment for retinitis pigmentosa, an orphan inherited retinal disease which leads to blindness and affects nearly two million worldwide.
  • SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration.

Yumanity Therapeutics Announces Strategic Research Collaboration and License Agreement with Merck Focused on Accelerating the Development of New Treatments for Neurodegenerative Diseases

Retrieved on: 
Wednesday, June 24, 2020
Brain, Nervous system, Branches of biology, Senescence, Dementia, Cognitive disorders, Frontal lobe, Temporal lobe, Frontotemporal lobar degeneration, Neurodegeneration, Amyotrophic lateral sclerosis, Degenerative disease

CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, a leader in the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that it has entered into a strategic research collaboration and license agreement with Merck (known as MSD outside the United States and Canada) focused on accelerating the development of new treatments for neurodegenerative diseases.

Key Points: 
  • CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, a leader in the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that it has entered into a strategic research collaboration and license agreement with Merck (known as MSD outside the United States and Canada) focused on accelerating the development of new treatments for neurodegenerative diseases.
  • Under the terms of the agreement, Merck will gain exclusive rights to two novel Yumanity pipeline programs for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD).
  • Yumanity and Merck will collaborate to advance the two preclinical programs during the research term, after which Merck has the right to continue clinical development and commercialization.
  • We look forward to working with scientists at Yumanity to advance research and evaluate the potential for therapeutic intervention in these neurodegenerative diseases.